Table of Contents
ISRN Gastroenterology
Volume 2012 (2012), Article ID 648183, 15 pages
http://dx.doi.org/10.5402/2012/648183
Review Article

Progress in Rectal Cancer Treatment

Department of Surgery, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium

Received 24 June 2012; Accepted 8 August 2012

Academic Editors: O. El Sibai and H. Kuwano

Copyright © 2012 Wim P. Ceelen. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. S. Galler, N. J. Petrelli, and S. P. Shakamuri, “Rectal cancer surgery: a brief history,” Surgical Oncology, vol. 20, no. 4, pp. 223–230, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. V. Lemmens, L. V. Steenbergen, M. Janssen-Heijnen, H. Martijn, H. Rutten, and J. W. Coebergh, “Trends in colorectal cancer in the south of the Netherlands 19752007: rectal cancer survival levels with colon cancer survival,” Acta Oncologica, vol. 49, no. 6, pp. 784–796, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. E. Pihl, E. S. R. Hughes, F. T. McDermott, W. R. Johnson, and H. Katrivessis, “Lung recurrence after curative surgery for colorectal cancer,” Diseases of the Colon and Rectum, vol. 30, no. 6, pp. 417–419, 1987. View at Google Scholar · View at Scopus
  4. R. Kirke, A. Rajesh, R. Verma, and M. J. G. Bankart, “Rectal cancer: incidence of pulmonary metastases on thoracic CT and correlation with T staging,” Journal of Computer Assisted Tomography, vol. 31, no. 4, pp. 569–571, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. H. Nozawa, E. Sunami, J. Nakajima, H. Nagawa, and J. Kitayama, “Synchronous and metachronous lung metastases in patients with colorectal cancer: a 20-year monocentric experience,” Experimental and Therapeutic Medicine, vol. 3, no. 3, pp. 449–456, 2012. View at Google Scholar
  6. D. Adeyemo and R. Hutchinson, “Preoperative staging of rectal cancer: pelvic MRI plus abdomen and pelvic CT. Does extrahepatic abdomen imaging matter? A case for routine thoracic CT,” Colorectal Disease, vol. 11, no. 3, pp. 259–263, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. D. R. Adams, G. J. Blatchford, K. M. Lin, C. A. Ternent, A. G. Thorson, and M. A. Christensen, “Use of preoperative ultrasound staging for treatment of rectal cancer,” Diseases of the Colon and Rectum, vol. 42, no. 2, pp. 159–166, 1999. View at Publisher · View at Google Scholar · View at Scopus
  8. S. R. Puli, M. L. Bechtold, J. B. K. Reddy, A. Choudhary, M. R. Antillon, and W. R. Brugge, “How good is endoscopic ultrasound in differentiating various t stages of rectal cancer? Meta-analysis and systematic review,” Annals of Surgical Oncology, vol. 16, no. 2, pp. 254–265, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Evans, U. Patel, and G. Brown, “Rectal cancer: primary staging and assessment after chemoradiotherapy,” Seminars in Radiation Oncology, vol. 21, no. 3, pp. 169–177, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. J. M. Fowler, C. E. Beagley, L. Blomqvist et al., “Extramural depth of tumor invasion at thin-section MR in patients with rectal cancer: results of the MERCURY study,” Radiology, vol. 243, no. 1, pp. 132–139, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. G. Brown, I. R. Daniels, R. J. Heald et al., “Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study,” British Medical Journal, vol. 333, no. 7572, pp. 779–782, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. G. Brown, A. G. Radcliffe, R. G. Newcombe, N. S. Dallimore, M. W. Bourne, and G. T. Williams, “Preoperative assessment of prognostic factors in rectal cancer using high-resolution magnetic resonance imaging,” British Journal of Surgery, vol. 90, no. 3, pp. 355–364, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. D. M. Koh, G. Brown, L. Temple et al., “Rectal cancer: mesorectal lymph nodes at MR imaging with USPIO versus histopathologic findings—initial observations,” Radiology, vol. 231, no. 1, pp. 91–99, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. D. M. Koh, C. George, L. Temple et al., “Diagnostic accuracy of nodal enhancement pattern of rectal cancer at MRI enhanced with ultrasmall superparamagnetic iron oxide: findings in pathologically matched mesorectal lymph nodes,” American Journal of Roentgenology, vol. 194, no. 6, pp. W505–W513, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. G. L. Beets, M. Lahaye, S. M. E. Engelen et al., “Can we predict the nodal status in primary rectal cancer accurately with USPIO MRI?” EJC Supplements, vol. 5, no. 4, pp. 236–236, 2007. View at Google Scholar
  16. D. M. J. Lambregts, G. L. Beets, M. Maas et al., “Accuracy of gadofosveset-enhanced MRI for nodal staging and restaging in rectal cancer,” Annals of Surgery, vol. 253, no. 3, pp. 539–545, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Chagnac, P. Herskovitz, T. Weinstein et al., “The peritoneal membrane in peritoneal dialysis patients: estimation of its functional surface area by applying stereologic methods to computerized tomography scans,” Journal of the American Society of Nephrology, vol. 10, no. 2, pp. 342–346, 1999. View at Google Scholar · View at Scopus
  18. J. Witowski, K. Ksiazek, C. Warnecke et al., “Role of mesothelial cell-derived granulocyte colony-stimulating factor in interleukin-17-induced neutrophil accumulation in the peritoneum,” Kidney International, vol. 71, no. 6, pp. 514–525, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. K. Bujko, A. Rutkowski, G. J. Chang, W. Michalski, E. Chmielik, and J. Kusnierz, “Is the 1-cm rule of distal bowel resection margin in rectal cancer based on clinical evidence? A systematic review,” Annals of Surgical Oncology, vol. 19, no. 3, pp. 801–808, 2012. View at Publisher · View at Google Scholar
  20. A. Rutkowski, M. Chwalinski, J. Oledzki et al., “Safe length of distal bowel margin in lower rectum cancer surgery,” Diseases of the Colon & Rectum, vol. 53, no. 4, pp. 544–544, 2010. View at Google Scholar
  21. R. J. Heald, E. M. Husband, and R. D. H. Ryall, “The mesorectum in rectal cancer surgery—the clue to pelvic recurrence?” British Journal of Surgery, vol. 69, no. 10, pp. 613–616, 1982. View at Google Scholar · View at Scopus
  22. R. J. Heald and R. D. H. Ryall, “Recurrence and survival after total mesorectal excision for rectal cancer,” The Lancet, vol. 1, no. 8496, pp. 1479–1482, 1986. View at Google Scholar · View at Scopus
  23. P. Quirke, M. F. Dixon, P. Durdey, and N. S. Williams, “Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. Histopathological study of lateral tumour spread and surgical excision,” The Lancet, vol. 2, no. 8514, pp. 996–999, 1986. View at Google Scholar · View at Scopus
  24. P. Quirke, P. Durdey, N. S. Williams, and M. F. Dixon, “Local recurrence after surgery for rectal adenocarcinoma results from incomplete removal,” The Journal of Pathology, vol. 149, no. 3, p. A228, 1986. View at Google Scholar
  25. A. Korzets, Y. Ori, D. Zevin et al., “A worrying thought—could there be a connection between encapsulating peritoneal sclerosis, tamoxifen and calciphylaxis?” Nephrology Dialysis Transplantation, vol. 21, no. 10, pp. 2975–2978, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. R. Schiessel, G. Novi, B. Holzer et al., “Technique and long-term results of intersphincteric resection for low rectal cancer,” Diseases of the Colon and Rectum, vol. 48, no. 10, pp. 1858–1865, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. E. Rullier, C. Laurent, F. Bretagnol, A. Rullier, V. Vendrely, and F. Zerbib, “Sphincter-saving resection for all rectal carcinomas: the end of the 2-cm distal rule,” Annals of Surgery, vol. 241, no. 3, pp. 465–469, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Chagnac, P. Herskovitz, Y. Ori et al., “Effect of increased dialysate volume on peritoneal surface area among peritoneal dialysis patients,” Journal of the American Society of Nephrology, vol. 13, no. 10, pp. 2554–2559, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. S. T. Martin, H. M. Heneghan, and D. C. Winter, “Systematic review of outcomes after intersphincteric resection for low rectal cancer,” British Journal of Surgery, vol. 99, no. 5, pp. 603–612, 2012. View at Google Scholar
  30. N. P. West, C. Anderin, K. J. E. Smith, T. Holm, P. Quirke, and E. Extralevator, “Multicentre experience with extralevator abdominoperineal excision for low rectal cancer,” British Journal of Surgery, vol. 97, no. 4, pp. 588–599, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. N. P. West, P. J. Finan, C. Anderin, J. Lindholm, T. Holm, and P. Quirke, “Evidence of the oncologic superiority of cylindrical abdominoperineal excision for low rectal cancer,” Journal of Clinical Oncology, vol. 26, no. 21, pp. 3517–3522, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Stelzner, C. Koehler, J. Stelzer, A. Sims, and H. Witzigmann, “Extended abdominoperineal excision vs. standard abdominoperineal excision in rectal cancer-a systematic overview,” International Journal of Colorectal Disease, vol. 26, no. 10, pp. 1227–1240, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. Y. Liang, G. Li, P. Chen, and J. Yu, “Laparoscopic versus open colorectal resection for cancer: a meta-analysis of results of randomized controlled trials on recurrence,” European Journal of Surgical Oncology, vol. 34, no. 11, pp. 1217–1224, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. E. Kuhry, W. Schwenk, R. Gaupset, U. Romild, and J. Bonjer, “Long-term outcome of laparoscopic surgery for colorectal cancer: a cochrane systematic review of randomised controlled trials,” Cancer Treatment Reviews, vol. 34, no. 6, pp. 498–504, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. G. Nandakumar and J. W. Fleshman, “Laparoscopy for rectal cancer,” Surgical Oncology Clinics of North America, vol. 19, no. 4, pp. 793–802, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. H. J. Bonjer, A. M. Lacy, E. Haglind et al., “Color II. A randomized clinical trial comparing laparoscopic and open surgery for rectal cancer,” Danish Medical Bulletin, vol. 56, no. 2, pp. 89–91, 2009. View at Google Scholar · View at Scopus
  37. S. Kitano, M. Inomata, A. Sato, K. Yoshimura, and Y. Moriya, “Randomized controlled trial to evaluate laparoscopic surgery for colorectal cancer: Japan clinical oncology group study JCOG 0404,” Japanese Journal of Clinical Oncology, vol. 35, no. 8, pp. 475–477, 2005. View at Publisher · View at Google Scholar · View at Scopus
  38. S. H. Baik, M. Gincherman, M. G. Mutch, E. H. Birnbaum, and J. W. Fleshman, “Laparoscopic vs open resection for patients with rectal cancer: comparison of perioperative outcomes and long-term survival,” Diseases of the Colon and Rectum, vol. 54, no. 1, pp. 6–14, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. H. J. Bonjer, E. Haglind, M. A. Cuesta, A. Fürst, van der Pas MHGM, and W. C. J. Hop, “Laparoscopic surgery versus open surgery for rectal cancer: short term outcomes of a randomized trial,” in Proceedings of the European Cancer Organisation (ECCO '11), Stockholm, Sweden, 2011.
  40. H. S. Tilney and P. P. Tekkis, “Extending the horizons of restorative rectal surgery: intersphincteric resection for low rectal cancer,” Colorectal Disease, vol. 10, no. 1, pp. 3–15, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. R. Gray, R. Hills, R. Stowe et al., “Adjuvant radiotherapy for rectal cancer: a systematic overview of 8507 patients from 22 randomised trials,” The Lancet, vol. 358, no. 9290, pp. 1291–1304, 2001. View at Publisher · View at Google Scholar · View at Scopus
  42. R. Sauer, H. Becker, W. Hohenberger et al., “Preoperative versus postoperative chemoradiotherapy for rectal cancer,” New England Journal of Medicine, vol. 351, no. 17, pp. 1731–1740, 2004. View at Publisher · View at Google Scholar · View at Scopus
  43. R. Suwinski, J. M. G. Taylor, and H. R. Withers, “Rapid growth of microscopic rectal cancer as a determinant of response to preoperative radiation therapy,” International Journal of Radiation Oncology Biology Physics, vol. 42, no. 5, pp. 943–951, 1998. View at Publisher · View at Google Scholar · View at Scopus
  44. G. A. Viani, E. J. Stefano, F. V. Soares, and S. L. Afonso, “Evaluation of biologic effective dose and schedule of fractionation for preoperative radiotherapy for rectal cancer: meta-analyses and meta-regression,” International Journal of Radiation Oncology Biology Physics, vol. 80, no. 4, pp. 985–991, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. E. Kapiteijn, C. A. M. Marijnen, I. D. Nagtegaal et al., “Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer,” New England Journal of Medicine, vol. 345, no. 9, pp. 638–646, 2001. View at Publisher · View at Google Scholar · View at Scopus
  46. W. Van Gijn, C. A. M. Marijnen, I. D. Nagtegaal et al., “Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial,” The Lancet Oncology, vol. 12, no. 6, pp. 575–582, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. C. A. M. Marijnen, I. D. Nagtegaal, E. Kapiteijn et al., “Radiotherapy does not compensate for positive resection margins in rectal cancer patients: report of a multicenter randomized trial,” International Journal of Radiation Oncology Biology Physics, vol. 55, no. 5, pp. 1311–1320, 2003. View at Publisher · View at Google Scholar · View at Scopus
  48. W. Ceelen, K. Fierens, Y. Van Nieuwenhove, and P. Pattyn, “Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer: a systematic review and meta-analysis,” International Journal of Cancer, vol. 124, no. 12, pp. 2966–2972, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. H. Birgisson, L. Påhlman, U. Gunnarsson, and B. Glimelius, “Occurrence of second cancers in patients treated with radiotherapy for rectal cancer,” Journal of Clinical Oncology, vol. 23, no. 25, pp. 6126–6131, 2005. View at Publisher · View at Google Scholar · View at Scopus
  50. H. Birgisson, L. Påhlman, U. Gunnarsson, and B. Glimelius, “Late gastrointestinal disorders after rectal cancer surgery with and without preoperative radiation therapy,” British Journal of Surgery, vol. 95, no. 2, pp. 206–213, 2008. View at Publisher · View at Google Scholar · View at Scopus
  51. M. M. Lange, M. Den Dulk, E. R. Bossema et al., “Risk factors for faecal incontinence after rectal cancer treatment,” British Journal of Surgery, vol. 94, no. 10, pp. 1278–1284, 2007. View at Publisher · View at Google Scholar · View at Scopus
  52. M. M. Lange, C. A. M. Marijnen, C. P. Maas et al., “Risk factors for sexual dysfunction after rectal cancer treatment,” European Journal of Cancer, vol. 45, no. 9, pp. 1578–1588, 2009. View at Publisher · View at Google Scholar · View at Scopus
  53. T. Latkauskas, H. Pauzas, I. Gineikiene et al., “Initial results of a randomized controlled trial comparing clinical and pathological downstaging of rectal cancer after preoperative short-course radiotherapy or long-term chemoradiotherapy, both with delayed surgery,” Colorectal Disease, vol. 14, no. 3, pp. 294–298, 2012. View at Google Scholar
  54. D. Pettersson, B. Cederniark, T. Holm et al., “Interim analysis of the Stockholm III trial of preoperative radiotherapy regimens for rectal cancer,” British Journal of Surgery, vol. 97, no. 4, pp. 580–587, 2010. View at Publisher · View at Google Scholar · View at Scopus
  55. C. Roedel, “Preoperative chemoradiotherapy and postoperative chemotherapy with 5-fluorouracil and oxaliplatin versus 5-fluorouracil alone in locally advanced rectal cancer: first results of the German CAO/ARO/AIO-04 randomized phase III trial,” Journal of Clinical Oncology, vol. 29, supplement, abstract LBA3505, 2011. View at Google Scholar
  56. C. Aschele, L. Cionini, S. Lonardi et al., “Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial,” Journal of Clinical Oncology, vol. 29, no. 20, pp. 2773–2780, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. J. P. Gérard, D. Azria, S. Gourgou-Bourgade et al., “Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial accord 12/0405-Prodige 2,” Journal of Clinical Oncology, vol. 28, no. 10, pp. 1638–1644, 2010. View at Publisher · View at Google Scholar · View at Scopus
  58. M. S. Roh, “The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04,” Journal of Clinical Oncology, vol. 29, supplement, abstract 3503, 2011. View at Google Scholar
  59. S. Boulis-Wassif, A. Gerard, and J. Loygue, “Final results of a randomized trial on the treatment of rectal cancer with preoperative radiotherapy alone or in combination with 5-fluorouracil, followed by radical surgery. Trial of the European Organization on Research and Treatment of Cancer gastrointestinal tract cancer cooperative group,” Cancer, vol. 53, no. 9, pp. 1811–1818, 1984. View at Google Scholar · View at Scopus
  60. J. F. Bosset, L. Collette, G. Calais et al., “Chemotherapy with preoperative radiotherapy in rectal cancer,” New England Journal of Medicine, vol. 355, no. 11, pp. 1114–1123, 2006. View at Publisher · View at Google Scholar · View at Scopus
  61. J. F. Bosset, G. Calais, L. Mineur et al., “Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results—EORTC 22921,” Journal of Clinical Oncology, vol. 23, no. 24, pp. 5620–5627, 2005. View at Publisher · View at Google Scholar · View at Scopus
  62. J. F. Bosset, G. Calais, A. Daban et al., “Preoperative chemoradiotherapy versus preoperative radiotherapy in rectal cancer patients: assessment of acute toxicity and treatment compliance: report of the 22921 randomised trial conducted by the EORTC Radiotherapy Group,” European Journal of Cancer, vol. 40, no. 2, pp. 219–224, 2004. View at Publisher · View at Google Scholar · View at Scopus
  63. J. P. Gérard, T. Conroy, F. Bonnetain et al., “Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203,” Journal of Clinical Oncology, vol. 24, no. 28, pp. 4620–4625, 2006. View at Publisher · View at Google Scholar · View at Scopus
  64. J. Gerard, T. Conroy, F. Bonnetain et al., “Preoperative (Preop) radiotherapy (RT) plus FU/folinic acid (FA) in T3.4 rectal cancers: preliminary results of the FFCD 92 03 randomized trial,” Journal of Radiation Oncology Biology Physics, vol. 60, no. 1, p. S138, 2004. View at Google Scholar
  65. K. Bujko, M. P. Nowacki, A. Nasierowska-Guttmejer et al., “Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy,” Radiotherapy and Oncology, vol. 72, no. 1, pp. 15–24, 2004. View at Publisher · View at Google Scholar · View at Scopus
  66. K. Bujko, M. P. Nowacki, A. Nasierowska-Guttmejer, W. Michalski, M. Bebenek, and M. Kryj, “Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer,” British Journal of Surgery, vol. 93, no. 10, pp. 1215–1223, 2006. View at Publisher · View at Google Scholar · View at Scopus
  67. K. Bujko, M. P. Nowacki, A. Nasierowska-Guttmejer et al., “Prediction of mesorectal nodal metastases after chemoradiation for rectal cancer: results of a randomised trial. Implication for subsequent local excision,” Radiotherapy and Oncology, vol. 76, no. 3, pp. 234–240, 2005. View at Publisher · View at Google Scholar · View at Scopus
  68. P. Rouanet, M. Rivoire, B. Lelong et al., “Sphincter preserving surgery after preoperative treatment for ultra-low rectal carcinoma. A French multicenter prospective trial: GRECCAR 1,” Journal of Clinical Oncology, vol. 24, no. 18, p. 152S, 2006. View at Google Scholar
  69. S. Ngan, “A randomized trial comparing local recurrence (LR) rates between short-course (SC) and long-course (LC) preoperative radiotherapy (RT) for clinical T3 rectal cancer: an intergroup trial (TROG, AGITG, CSSANZ, RACS),” Journal of Clinical Oncology, vol. 28, 15s, abstract 3509, 2010. View at Google Scholar
  70. R. Wollman, J. Yahalom, R. Maxy, J. Pinto, and Z. Fuks, “Effect of epidermal growth factor on the growth and radiation sensitivity of human breast cancer cells in vitro,” International Journal of Radiation Oncology Biology Physics, vol. 30, no. 1, pp. 91–98, 1994. View at Google Scholar · View at Scopus
  71. R. Kopp, E. Rothbauer, E. Mueller, F. W. Schildberg, K. W. Jauch, and A. Pfeiffer, “Reduced survival of rectal cancer patients with increased tumor epidermal growth factor receptor levels,” Diseases of the Colon and Rectum, vol. 46, no. 10, pp. 1391–1399, 2003. View at Publisher · View at Google Scholar · View at Scopus
  72. R. D. Hofheinz, K. Horisberger, C. Woernle et al., “Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer,” International Journal of Radiation Oncology Biology Physics, vol. 66, no. 5, pp. 1384–1390, 2006. View at Publisher · View at Google Scholar · View at Scopus
  73. S. Y. Kim, Y. S. Hong, D. Y. Kim et al., “Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter phase II study,” International Journal of Radiation Oncology, Biology, Physics, vol. 81, no. 3, pp. 677–683, 2011. View at Publisher · View at Google Scholar · View at Scopus
  74. J. P. Machiels, C. Sempoux, P. Scalliet et al., “Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer,” Annals of Oncology, vol. 18, no. 4, pp. 738–744, 2007. View at Publisher · View at Google Scholar · View at Scopus
  75. C. Rödel, D. Arnold, M. Hipp et al., “Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer,” International Journal of Radiation Oncology Biology Physics, vol. 70, no. 4, pp. 1081–1086, 2008. View at Publisher · View at Google Scholar · View at Scopus
  76. S. Y. Kim, Y. S. Hong, D. Y. Kim et al., “Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter phase II study,” International Journal of Radiation Oncology, Biology, Physics, vol. 81, no. 3, pp. 677–683, 2011. View at Publisher · View at Google Scholar · View at Scopus
  77. V. Velenik, J. Ocvirk, I. Oblak, and F. Anderluh, “A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer,” European Journal of Surgical Oncology, vol. 36, no. 3, pp. 244–250, 2010. View at Publisher · View at Google Scholar · View at Scopus
  78. A. Dewdney, D. Cunningham, J. Tabernero et al., “Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C),” Journal of Clinical Oncology, vol. 30, no. 14, pp. 1620–1627, 2012. View at Publisher · View at Google Scholar
  79. R. P. M. Dings, M. Loren, H. Heun et al., “Scheduling of radiation with angiogenesis inhibitors anginex and avastin improves therapeutic outcome via vessel normalization,” Clinical Cancer Research, vol. 13, no. 11, pp. 3395–3402, 2007. View at Publisher · View at Google Scholar · View at Scopus
  80. R. K. Jain, “Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy,” Science, vol. 307, no. 5706, pp. 58–62, 2005. View at Publisher · View at Google Scholar · View at Scopus
  81. D. H. Gorski, M. A. Beckett, N. T. Jaskowiak et al., “Blockade of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation,” Cancer Research, vol. 59, no. 14, pp. 3374–3378, 1999. View at Google Scholar · View at Scopus
  82. C. H. Crane, C. Eng, B. W. Feig et al., “Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer,” International Journal of Radiation Oncology Biology Physics, vol. 76, no. 3, pp. 824–830, 2010. View at Publisher · View at Google Scholar · View at Scopus
  83. T. Dipetrillo, V. Pricolo, J. Lagares-Garcia et al., “Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation for rectal cancer,” International Journal of Radiation Oncology, Biology, Physics, vol. 82, no. 1, pp. 124–129, 2012. View at Publisher · View at Google Scholar · View at Scopus
  84. G. Gasparini, F. Torino, T. Ueno et al., “A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer,” Angiogenesis, vol. 15, no. 1, pp. 141–150, 2012. View at Publisher · View at Google Scholar
  85. T. Hohler, M. Klein, K. Dellas et al., “Preoperative chemoradiation (CRT) with concurrent capecitabine (Cap), oxaliplatin (Ox) and bevacizumab (Bev) in patients with locally advanced rectal cancer (RC): effects on pathological complete response (pCR) and surgical complications,” Onkologie, vol. 34, p. 220, 2011. View at Publisher · View at Google Scholar
  86. H. Kennecke, S. Berry, R. Wong et al., “Pre-operative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: a phase II trial,” European Journal of Cancer, vol. 48, no. 1, pp. 37–45, 2012. View at Publisher · View at Google Scholar · View at Scopus
  87. G. Resch, A. De Vries, D. Öfner et al., “Preoperative treatment with capecitabine, bevacizumab and radiotherapy for primary locally advanced rectal cancer—a two stage phase II clinical trial,” Radiotherapy and Oncology, vol. 102, no. 1, pp. 10–13, 2012. View at Publisher · View at Google Scholar · View at Scopus
  88. D. R. Spigel, J. C. Bendell, M. McCleod et al., “Phase II study of bevacizumab and chemoradiation in the preoperative or adjuvant treatment of patients with stage II/III rectal cancer,” Clinical Colorectal Cancer, vol. 11, no. 1, pp. 45–52, 2012. View at Google Scholar
  89. K. Uehara, S. Ishiguro, E. Sakamoto et al., “Phase II trial of neoadjuvant chemotherapy with XELOX plus bevacizumab for locally advanced rectal cancer,” Japanese Journal of Clinical Oncology, vol. 41, no. 8, Article ID hyr084, pp. 1041–1044, 2011. View at Publisher · View at Google Scholar · View at Scopus
  90. V. Velenik, J. Ocvirk, M. Music et al., “Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study,” Radiation Oncology, vol. 6, article 105, 2011. View at Google Scholar
  91. C. G. Willett, D. G. Duda, E. Di Tomaso et al., “Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study,” Journal of Clinical Oncology, vol. 27, no. 18, pp. 3020–3026, 2009. View at Publisher · View at Google Scholar · View at Scopus
  92. T. Dipetrillo, V. Pricolo, J. Lagares-Garcia et al., “Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation for rectal cancer,” International Journal of Radiation Oncology, Biology, Physics, vol. 82, no. 1, pp. 124–129, 2012. View at Publisher · View at Google Scholar · View at Scopus
  93. C. Marijnen, “Preoperative chemoradiotherapy regimen with capecitabine and bevacizumab in locally advanced rectal cancer: a feasibility study of the Dutch Colorectal Cancer Group (DCCG),” Journal of Clinical Oncology, vol. 26, supplement, abstract 15040, 2008. View at Google Scholar
  94. C. Fernández-Martos, C. Pericay, J. Aparicio et al., “Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo Cáncer de Recto 3 study,” Journal of Clinical Oncology, vol. 28, no. 5, pp. 859–865, 2010. View at Publisher · View at Google Scholar · View at Scopus
  95. R. Maréchal, “Chemotherapy induction followed by preoperative chemoradiation versus preoperative chemoradiation alone in locally advanced rectal cancer (LARC): a randomized controlled phase II study,” Journal of Clinical Oncology, vol. 28, 15s, abstract 3637, 2010. View at Google Scholar
  96. M. Nogué, A. Salud, P. Vicente et al., “Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study,” Oncologist, vol. 16, no. 5, pp. 614–620, 2011. View at Publisher · View at Google Scholar · View at Scopus
  97. A. Habr-Gama, R. O. Perez, J. Sabbaga, W. Nadalin, G. P. São Julião, and J. Gama-Rodrigues, “Increasing the rates of complete response to neoadjuvant chemoradiotherapy for distal rectal cancer: results of a prospective study using additional chemotherapy during the resting period,” Diseases of the Colon and Rectum, vol. 52, no. 12, pp. 1927–1934, 2009. View at Publisher · View at Google Scholar · View at Scopus
  98. J. Garcia-Aguilar, D. D. Smith, K. Avila, E. K. Bergsland, P. Chu, and R. M. Krieg, “Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a multicenter, nonrandomized phase II prospective trial,” Annals of Surgery, vol. 254, no. 1, pp. 97–102, 2011. View at Publisher · View at Google Scholar · View at Scopus
  99. D. Schrag, “Neoadjuvant FOLFOX-bev, without radiation, for locally advanced rectal cancer,” Journal of Clinical Oncology, vol. 28, 15s, abstract 3511, 2010. View at Google Scholar
  100. I. Chau, M. Allen, D. Cunningham et al., “Neoadjuvant systemic fluorouracil and mitomycin C prior to synchronous chemoradiation is an effective strategy in locally advanced rectal cancer,” British Journal of Cancer, vol. 88, no. 7, pp. 1017–1024, 2003. View at Publisher · View at Google Scholar · View at Scopus
  101. Y. J. Chua, Y. Barbachano, D. Cunningham et al., “Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial,” The Lancet Oncology, vol. 11, no. 3, pp. 241–248, 2010. View at Publisher · View at Google Scholar · View at Scopus
  102. J. V. Schou, F. O. Larsen, L. Rasch et al., “Induction chemotherapy with capecitabine and oxaliplatin followed by chemoradiotherapy before total mesorectal excision in patients with locally advanced rectal cancer,” Annals of Oncology. In press.
  103. J. Garcia-Aguilar, Q. Shi, C. R. Thomas et al., “A Phase II trial of neoadjuvant chemoradiation and local excision for T2N0 rectal cancer: preliminary results of the ACOSOG Z6041 trial,” Annals of Surgical Oncology, vol. 19, no. 2, pp. 384–391, 2012. View at Publisher · View at Google Scholar · View at Scopus
  104. S. G. Yeo, D. Y. Kim, T. H. Kim et al., “Local excision following pre-operative chemoradiotherapyinduced downstaging for selected cT3 distal rectal cancer,” Japanese Journal of Clinical Oncology, vol. 40, no. 8, Article ID hyq062, pp. 754–760, 2010. View at Publisher · View at Google Scholar · View at Scopus
  105. G. G. Callender, P. Das, M. A. Rodriguez-Bigas et al., “Local excision after preoperative chemoradiation results in an equivalent outcome to total mesorectal excision in selected patients with T3 rectal cancer,” Annals of Surgical Oncology, vol. 17, no. 2, pp. 441–447, 2010. View at Publisher · View at Google Scholar · View at Scopus
  106. Y. Kundel, R. Brenner, O. Purim et al., “Is local excision after complete pathological response to neoadjuvant chemoradiation for rectal cancer an acceptable treatment option?” Diseases of the Colon and Rectum, vol. 53, no. 12, pp. 1624–1631, 2010. View at Publisher · View at Google Scholar · View at Scopus
  107. K. Bujko, P. Richter, M. Kołodziejczyk et al., “Preoperative radiotherapy and local excision of rectal cancer with immediate radical re-operation for poor responders,” Radiotherapy and Oncology, vol. 92, no. 2, pp. 195–201, 2009. View at Publisher · View at Google Scholar · View at Scopus
  108. J. W. Huh, E. J. Jung, Y. A. Park, K. Y. Lee, and S. K. Sohn, “Preoperative chemoradiation followed by transanal excision for rectal cancer,” Journal of Surgical Research, vol. 148, no. 2, pp. 244–250, 2008. View at Publisher · View at Google Scholar · View at Scopus
  109. R. M. Nair, E. M. Siegel, D. T. Chen et al., “Long-term results of transanal excision after neoadjuvant chemoradiation for T2 and T3 adenocarcinomas of the rectum,” Journal of Gastrointestinal Surgery, vol. 12, no. 10, pp. 1797–1805, 2008. View at Publisher · View at Google Scholar · View at Scopus
  110. M. Guerrieri, M. Baldarelli, L. Organetti et al., “Transanal endoscopic microsurgery for the treatment of selected patients with distal rectal cancer: 15 Years experience,” Surgical Endoscopy and Other Interventional Techniques, vol. 22, no. 9, pp. 2030–2035, 2008. View at Publisher · View at Google Scholar · View at Scopus
  111. C. Park, W. Lee, S. Han, S. Yun, and H. K. Chun, “Transanal local excision for preoperative concurrent chemoradiation therapy for distal rectal cancer in selected patients,” Surgery Today, vol. 37, no. 12, pp. 1068–1072, 2007. View at Publisher · View at Google Scholar · View at Scopus
  112. M. Caricato, D. Borzomati, F. Ausania et al., “Complementary use of local excision and transanal endoscopic microsurgery for rectal cancer after neoadjuvant chemoradiation,” Surgical Endoscopy and Other Interventional Techniques, vol. 20, no. 8, pp. 1203–1207, 2006. View at Publisher · View at Google Scholar · View at Scopus
  113. M. Bonnen, C. Crane, J. N. Vauthey et al., “Long-term results using local excision after preoperative chemoradiation among selected T3 rectal cancer patients,” International Journal of Radiation Oncology Biology Physics, vol. 60, no. 4, pp. 1098–1105, 2004. View at Publisher · View at Google Scholar · View at Scopus
  114. L. Ruo, J. G. Guillem, B. D. Minsky, S. H. Q. Quan, P. B. Paty, and A. M. Cohen, “Preoperative radiation with or without chemotherapy and full-thickness transanal excision for selected T2 and T3 distal rectal cancers,” International Journal of Colorectal Disease, vol. 17, no. 1, pp. 54–58, 2002. View at Publisher · View at Google Scholar · View at Scopus
  115. S. R. Schell, R. A. Zlotecki, W. M. Mendenhall, R. W. Marsh, J. N. Vauthey, and E. M. Copeland, “Transanal excision of locally advanced rectal cancers downstaged using neoadjuvant chemoradiotherapy,” Journal of the American College of Surgeons, vol. 194, no. 5, pp. 584–591, 2002. View at Publisher · View at Google Scholar · View at Scopus
  116. C. J. Kim, T. J. Yeatman, D. Coppola et al., “Local excision of T2 and T3 rectal cancers after downstaging chemoradiation,” Annals of Surgery, vol. 234, no. 3, pp. 352–359, 2001. View at Publisher · View at Google Scholar · View at Scopus
  117. M. Mohiuddin, G. Marks, and J. Bannon, “High-dose preoperative radiation and full thickness local excision: a new option for selected T3 distal rectal cancers,” International Journal of Radiation Oncology Biology Physics, vol. 30, no. 4, pp. 845–849, 1994. View at Google Scholar · View at Scopus
  118. S. H. Petersen, H. Harling, L. T. Kirkeby, P. Wille-Jorgensen, and S. Mocellin, “Postoperative adjuvant chemotherapy in rectal cancer operated for cure,” Cochrane Database of Systematic Reviews, vol. 3, Article ID CD004078, 2012. View at Google Scholar
  119. R. Gray, J. Barnwell, C. McConkey et al., “Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study,” The Lancet, vol. 370, no. 9604, pp. 2020–2029, 2007. View at Publisher · View at Google Scholar · View at Scopus
  120. M. Maas, P. J. Nelemans, V. Valentini et al., “Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data,” The Lancet Oncology, vol. 11, no. 9, pp. 835–844, 2010. View at Publisher · View at Google Scholar · View at Scopus
  121. L. Collette, J. F. Bosset, M. Den Dulk et al., “Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group,” Journal of Clinical Oncology, vol. 25, no. 28, pp. 4379–4386, 2007. View at Publisher · View at Google Scholar · View at Scopus
  122. K. Bujko, R. Glynne-Jones, and M. Bujko, “Does adjuvant fluoropyrimidine-based chemotherapy provide a benefit for patients with resected rectal cancer who have already received neoadjuvant radiochemotherapy? A systematic review of randomised trials,” Annals of Oncology, vol. 21, no. 9, pp. 1743–1750, 2010. View at Publisher · View at Google Scholar · View at Scopus
  123. L. Cionini, “Randomized study of postoperative chemotherapy (CT) after preoperative chemoradiation (CTRT) in locally advanced rectal cancer (LARC): preliminary results,” European Journal of Cancer, vol. 37, supplement 6, p. S300, 2001. View at Google Scholar
  124. R. Li, “Combination of surgery, radiotherapy and chemotherapy for rectal cancer—a 423 case report,” Zhonghua Zhong Liu Za Zhi, vol. 14, no. 3, pp. 213–215, 1992. View at Google Scholar · View at Scopus
  125. R. K. S. Wong, V. Tandan, S. De Silva, and A. Figueredo, “Pre-operative radiotherapy and curative surgery for the management of localized rectal carcinoma,” Cochrane Database of Systematic Reviews, no. 2, Article ID CD002102, 2007. View at Publisher · View at Google Scholar · View at Scopus
  126. S. Cilla, L. Caravatta, V. Picardi et al., “Volumetric modulated arc therapy with simultaneous integrated boost for locally advanced rectal cancer,” Clinical Oncology, vol. 24, no. 4, pp. 261–268, 2012. View at Publisher · View at Google Scholar · View at Scopus
  127. B. Engels, K. Tournel, H. Everaert et al., “Phase II study of preoperative helical tomotherapy with a simultaneous integrated boost for rectal cancer,” International Journal of Radiation Oncology Biology Physics, vol. 83, no. 1, pp. 142–148, 2012. View at Google Scholar
  128. J. M. Samuelian, M. D. Callister, J. B. Ashman, T. M. Young-Fadok, M. J. Borad, and L. L. Gunderson, “Reduced acute bowel toxicity in patients treated with intensity-modulated radiotherapy for rectal cancer,” International Journal of Radiation Oncology, Biology, Physics, vol. 82, no. 5, pp. 1981–1987, 2012. View at Publisher · View at Google Scholar · View at Scopus
  129. W. Duthoy, W. De Gersem, K. Vergote et al., “Clinical implementation of intensity-modulated arc therapy (IMAT) for rectal cancer,” International Journal of Radiation Oncology Biology Physics, vol. 60, no. 3, pp. 794–806, 2004. View at Publisher · View at Google Scholar · View at Scopus
  130. B. Engels, M. De Ridder, K. Tournel et al., “Preoperative helical tomotherapy and megavoltage computed tomography for rectal cancer: impact on the irradiated volume of small bowel,” International Journal of Radiation Oncology Biology Physics, vol. 74, no. 5, pp. 1476–1480, 2009. View at Publisher · View at Google Scholar · View at Scopus
  131. J. P. Gerard, O. Chapet, C. Nemoz et al., “Improved sphincter preservation in low rectal cancer with high-dose preoperative radiotherapy: the Lyon R96-02 randomized trial,” Journal of Clinical Oncology, vol. 22, no. 12, pp. 2404–2409, 2004. View at Publisher · View at Google Scholar · View at Scopus
  132. J. P. Gerard, O. Chapet, A. Ramaioli, and P. Romestaing, “Long-term control of T2-T3 rectal adenocarcinoma with radiotherapy alone,” International Journal of Radiation Oncology Biology Physics, vol. 54, no. 1, pp. 142–149, 2002. View at Publisher · View at Google Scholar · View at Scopus
  133. J. P. Gerard, P. Romestaing, J. M. Ardiet, and F. Mornex, “Endocavitary radiation therapy,” Seminars in Radiation Oncology, vol. 8, no. 1, pp. 13–23, 1998. View at Publisher · View at Google Scholar · View at Scopus
  134. J. P. Gerard, P. Romestaing, and O. Chapet, “Radiotherapy alone in the curative treatment of rectal carcinoma,” The Lancet Oncology, vol. 4, no. 3, pp. 158–166, 2003. View at Publisher · View at Google Scholar · View at Scopus
  135. J. P. Gérard, A. S. Myint, O. Croce et al., “Renaissance of contact x-ray therapy for treating rectal cancer,” Expert Review of Medical Devices, vol. 8, no. 4, pp. 483–492, 2011. View at Publisher · View at Google Scholar · View at Scopus
  136. A. S. Myint, “Renaissance of contact radiotherapy with RT 50 Papillon machine: a revival of new treatment option for early low rectal cancer?” Journal of Clinical Oncology, supplement, abstract e14149, 2012. View at Google Scholar
  137. F. Lim and R. Glynne-Jones, “Chemotherapy/chemoradiation in anal cancer: a systematic review,” Cancer Treatment Reviews, vol. 37, no. 7, pp. 520–532, 2011. View at Publisher · View at Google Scholar · View at Scopus
  138. A. Habr-Gama, R. O. Perez, G. P. São Julião, I. Proscurshim, and J. Gama-Rodrigues, “Nonoperative approaches to rectal cancer: a critical evaluation,” Seminars in Radiation Oncology, vol. 21, no. 3, pp. 234–239, 2011. View at Publisher · View at Google Scholar · View at Scopus
  139. P. Sanghera, D. W. Y. Wong, C. C. McConkey, J. I. Geh, and A. Hartley, “Chemoradiotherapy for rectal cancer: an updated analysis of factors affecting pathological response,” Clinical Oncology, vol. 20, no. 2, pp. 176–183, 2008. View at Publisher · View at Google Scholar · View at Scopus
  140. J. W. Huh, Y. A. Park, E. J. Jung, K. Y. Lee, and S. K. Sohn, “Accuracy of endorectal ultrasonography and computed tomography for restaging rectal cancer after preoperative chemoradiation,” Journal of the American College of Surgeons, vol. 207, no. 1, pp. 7–12, 2008. View at Publisher · View at Google Scholar · View at Scopus
  141. C. Kristiansen, A. Loft, A. K. Berthelsen et al., “PET/CT and histopathologic response to preoperative chemoradiation therapy in locally advanced rectal cancer,” Diseases of the Colon and Rectum, vol. 51, no. 1, pp. 21–25, 2008. View at Publisher · View at Google Scholar · View at Scopus
  142. A. Suppiah, I. A. Hunter, J. Cowley et al., “Magnetic resonance imaging accuracy in assessing tumour down-staging following chemoradiation in rectal cancer,” Colorectal Disease, vol. 11, no. 3, pp. 249–253, 2009. View at Publisher · View at Google Scholar · View at Scopus
  143. R. O. Perez, A. Habr-Gama, G. V. Pereira et al., “Role of biopsies in patients with residual rectal cancer following neoadjuvant chemoradiation after downsizing: can they rule out persisting cancer?” Colorectal Disease, vol. 14, no. 6, pp. 714–720, 2012. View at Publisher · View at Google Scholar
  144. R. O. Perez, A. Habr-Gama, G. P. S. Julião, I. Proscurshim, A. S. Neto, and J. Gama-Rodrigues, “Transanal endoscopic microsurgery for residual rectal cancer after neoadjuvant chemoradiation therapy is associated with significant immediate pain and hospital readmission rates,” Diseases of the Colon and Rectum, vol. 54, no. 5, pp. 545–551, 2011. View at Publisher · View at Google Scholar · View at Scopus
  145. G. M. J. Bokkerink, E. J. R. de Graaf, C. J. A. Punt et al., “The CARTS study: chemoradiation therapy for rectal cancer in the distal rectum followed by organ-sparing transanal endoscopic microsurgery,” BMC Surgery, vol. 11, article 34, 2011. View at Google Scholar
  146. A. Dzik-Jurasz, C. Domenig, M. George et al., “Diffusion MRI for prediction of response of rectal cancer to chemoradiation,” The Lancet, vol. 360, no. 9329, pp. 307–308, 2002. View at Publisher · View at Google Scholar · View at Scopus
  147. A. F. DeVries, C. Kremser, P. A. Hein et al., “Tumor microcirculation and diffusion predict therapy outcome for primary rectal carcinoma,” International Journal of Radiation Oncology Biology Physics, vol. 56, no. 4, pp. 958–965, 2003. View at Publisher · View at Google Scholar · View at Scopus
  148. P. A. Hein, C. Kremser, W. Judmaier et al., “Diffusion-weighted magnetic resonance imaging for monitoring diffusion changes in rectal carcinoma during combined, preoperative chemoradiation: preliminary results of a prospective study,” European Journal of Radiology, vol. 45, no. 3, pp. 214–222, 2003. View at Publisher · View at Google Scholar · View at Scopus
  149. L. Curvo-Semedo, D. M. J. Lambregts, M. Maas et al., “Rectal cancer: assessment of complete response to preoperative combined radiation therapy with chemotherapy-conventional MR volumetry versus diffusion-weighted MR imaging,” Radiology, vol. 260, no. 3, pp. 734–743, 2011. View at Google Scholar
  150. S. H. Kim, J. Y. Lee, J. M. Lee, J. K. Han, and B. I. Choi, “Apparent diffusion coefficient for evaluating tumour response to neoadjuvant chemoradiation therapy for locally advanced rectal cancer,” European Radiology, vol. 21, no. 5, pp. 987–995, 2011. View at Publisher · View at Google Scholar · View at Scopus
  151. Y. S. Sun, X. P. Zhang, L. Tang et al., “Locally advanced rectal carcinoma treated with preoperative chemotherapy and radiation therapy: preliminary analysis of diffusion-weighted MR imaging for early detection of tumor histopathologic downstaging,” Radiology, vol. 254, no. 1, pp. 170–178, 2010. View at Publisher · View at Google Scholar · View at Scopus
  152. B. M. Ghadimi, M. Grade, M. J. Difilippantonio et al., “Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy,” Journal of Clinical Oncology, vol. 23, no. 9, pp. 1826–1838, 2005. View at Publisher · View at Google Scholar · View at Scopus
  153. K. H. Brettingham-Moore, C. P. Duong, D. M. Greenawalt et al., “Pretreatment transcriptional profiling for predicting response to neoadjuvant chemoradiotherapy in rectal adenocarcinoma,” Clinical Cancer Research, vol. 17, no. 9, pp. 3039–3047, 2011. View at Publisher · View at Google Scholar · View at Scopus
  154. E. Balboa, G. Duran, M. J. Lamas et al., “Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: high incidence of somatic mutations and their relation with response,” Pharmacogenomics, vol. 11, no. 6, pp. 747–761, 2010. View at Publisher · View at Google Scholar · View at Scopus
  155. S. Brophy, K. M. Sheehan, D. A. McNamara, J. Deasy, D. J. Bouchier-Hayes, and E. W. Kay, “GLUT-1 expression and response to chemoradiotherapy in rectal cancer,” International Journal of Cancer, vol. 125, no. 12, pp. 2778–2782, 2009. View at Publisher · View at Google Scholar · View at Scopus
  156. E. Casado, V. M. García, J. J. Sánchez et al., “A combined strategy of SAGE and quantitative PCR provides a 13-gene signature that predicts preoperative chemoradiotherapy response and outcome in rectal cancer,” Clinical Cancer Research, vol. 17, no. 12, pp. 4145–4154, 2011. View at Publisher · View at Google Scholar · View at Scopus
  157. U. Drebber, M. Lay, I. Wedemeyer et al., “Altered levels of the onco-microRNA 21 and the tumor-supressor microRNAs 143 and 145 in advanced rectal cancer indicate successful neoadjuvant chemoradiotherapy,” International Journal of Oncology, vol. 39, no. 2, pp. 409–415, 2011. View at Publisher · View at Google Scholar · View at Scopus
  158. J. Garcia-Aguilar, Z. Chen, D. D. Smith et al., “Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer,” Annals of Surgery, vol. 254, no. 3, pp. 486–492, 2011. View at Google Scholar
  159. A. Ho-Pun-Cheung, E. Assenat, C. Bascoul-Mollevi et al., “A large-scale candidate gene approach identifies SNPs in SOD2 and IL13 as predictive markers of response to preoperative chemoradiation in rectal cancer,” Pharmacogenomics Journal, vol. 11, no. 6, pp. 437–443, 2011. View at Publisher · View at Google Scholar · View at Scopus
  160. Y. Toiyama, Y. Inoue, S. Saigusa et al., “Gene expression profiles of epidermal growth factor receptor, vascular endothelial growth factor and hypoxia-inducible factor-1 with special reference to local responsiveness to neoadjuvant chemoradiotherapy and disease recurrence after rectal cancer surgery,” Clinical Oncology, vol. 22, no. 4, pp. 272–280, 2010. View at Publisher · View at Google Scholar · View at Scopus